GlassScriptPhysician profile
Hina Anjum
NPI 1336409986
$696.53
in general payments reported to CMS, 2019-2025
15 companies · $15.55 in 2025
The $15.55 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $282 · 2020: $44.13 · 2021: $69.28 · 2022: $163 · 2023: $43.61 · 2024: $79.40 · 2025: $15.55.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $139.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $138.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $176.59 | 2021-2024 | Farxiga |
| Janssen Pharmaceuticals, INC | $101.04 | 2019 | |
| Amgen INC. | $99.07 | 2019-2025 | Repatha, Otezla, Otezla |
| Glaxosmithkline, LLC. | $81.84 | 2019-2024 | Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.12 | 2019-2021 | |
| Integra Lifesciences Corporation | $33.98 | 2024 | Integra, Omnigraft, Integra Dermal Regeneration Template |
| Pfizer INC. | $31.52 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $22.86 | 2019 | |
| Amarin Pharma, INC. | $22.05 | 2019 | |
| Novo Nordisk INC | $15.53 | 2019 | |
| Abbott Laboratories | $14.96 | 2021 | |
| Dexcom, INC. | $14.71 | 2022 | |
| Novartis Pharmaceuticals Corporation | $13.09 | 2019 | |
| Abbvie INC. | $12.96 | 2022 | |
| Allergan, INC. | $12.21 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hina Anjum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.